Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | AGXT | P21549 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681250 | 0.86 | IDO1 (0.41) | TSHRSLC6A2TAAR1PTPN1LMNA | |
| SCHEMBL1835373 | 0.84 | ESR1 (0.52) | ALDH1A1SLC6A2TAAR1PTPN1LMNA | |
| SCHEMBL13258020 | 0.83 | TSHR (0.45) | TSHRTRPA1ALDH1A1PTPN1CES2 | |
| Phenol SCHEMBL28851094 | 0.82 | LMNA (0.44) | TSHRTRPA1ALDH1A1SLC6A2TAAR1 | |
| SCHEMBL6827641 | 0.79 | MAOA (0.42) | TSHRALDH1A1SLC6A2TAAR1PTPN1 | |
| SCHEMBL21327698 | 0.75 | TSHR (0.48) | TSHRALDH1A1SLC6A2TAAR1PTPN1 | |
| SCHEMBL23652211 | 0.74 | TSHR (0.43) | TSHRTRPA1ALDH1A1SLC6A2TAAR1 | |
| SCHEMBL28653302 | 0.74 | TAAR1 (0.50) | TSHRTRPA1ALDH1A1SLC6A2TAAR1 | |
| SCHEMBL12879586 | 0.74 | TSHR (0.46) | TSHRALDH1A1SLC6A2TAAR1LMNA | |
| SCHEMBL8089474 | 0.73 | TSHR (0.71) | TSHRTRPA1ALDH1A1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813611-B1 | 1-SUBSTITUTED-3- BETA-D-GLYCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2014-10-01 | — | — | EP | disclosed |
| EP-1813611-B1 | 1-SUBSTITUTED-3- BETA-D-GLYCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2014-10-01 | — | — | EP | disclosed |
| US-7750145-B2 | 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-7750145-B2 | 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20090074738-A1 | 1-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090074738-A1 | 1-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1813611-A1 | 1-SUBSTITUTED-3- BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1813611-A1 | 1-SUBSTITUTED-3- BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074738-A1 | 1-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME | SLC5A1, SLC5A2, UGGT1 | TSHR 3796/4885TRPA1 1311/4885ALDH1A1 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.